CRBU

Caribou Biosciences, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-05

Figures on this page computed 2026-11-08 13:38 UTC

Last close

0.44USD

Market data, 2026-11-04

CRBU: weekly closes from 2.14 on 2026-05-15 to 0.44 on 2026-11-04, a move of -79.2%. Prices in USD.

Weekly closes, 2026-05-15 to 2026-11-04

Over that span: -79.2%

Except where said otherwise: 10-K for 2025, filed 2026-03-05

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-05
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-13
The filing itself
-1327.4%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself
-1006.8%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Growth is the furthest below its sector's middle: 0.30 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.80x

1.66x

1.41x

n/a

0.08x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-05

Sales0.80x
Its own average over 7 years, 13.9M.
Profit1.66x
Its own average over 7 years, -89.1M.
Free cash flow1.41x
Its own average over 7 years, -79.8M.
Debtn/a
Its own average over 0 years.
Price0.08x
Its own average over 6 years, 6. Market data, 2026-11-04

Price is furthest from its own average, at 0.08 times.

The filed years, as a table

Each line is 100 at 2019-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2019-12-31	100.0	n/a
2020-12-31	213.6	n/a
2021-12-31	165.8	100.0
2022-12-31	239.3	192.0
2023-12-31	595.7	233.1
2024-12-31	172.7	285.2
2025-12-31	192.8	294.9

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001619856-26-000008
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001619856-26-000008
Reported in: USD

The filing itself

Figures behind the shape

Growth

-2.0%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate-2.0%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income0.7%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

-121.2%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-13
The filing itself
Return on equity-121.2%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-13
The filing itself
Return on assets-84.5%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-13
The filing itself

Margins

-1329.4%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross marginn/a
We do not hold this figure for this company, so there is nothing to place.
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself
Operating margin-1329.4%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself
Net margin-1327.4%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself
Free cash flow margin-1006.8%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself

Price

0.3x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-05
The filing itself
Price to book0.3x10-Q for 2025, filed 2026-08-13
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001619856-26-000055
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-13
- computed
- 10-K for 2025, filed 2026-03-05
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-05
The filing itself
Price to sales ratio3.8x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself

Safety

5.71

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-08-13
The filing itself
Current ratio5.7110-Q for 2025, filed 2026-08-13
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001619856-26-000055
Reported in
USD
- 10-Q for 2025, filed 2026-08-13
- 10-Q for 2025, filed 2026-08-13
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself
Altman Z-Score-6.20
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-05
- Computed from the 10-K for 2025, filed 2026-03-05
- Computed from the 10-K for 2025, filed 2026-03-05
- Computed from the 10-K for 2025, filed 2026-03-05
- Computed from the 10-K for 2025, filed 2026-03-05

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001619856-26-000008
Reported in
USD
- 10-K for 2025, filed 2026-03-05
- Computed from the 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.